Spondyloarthritis & psoriatic arthritis
Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage
Main finding · New-onset PsAResult — go to the resultHazard ratio 11.7 95% CI 1.57–86.7Authors' conclusion
The probability of PsA development among subclinical PsA was relatively high, emphasising the importance of emergent musculoskeletal symptoms when aiming for PsA prevention. Joint swelling was the dominant feature in new-onset PsA, likely reflecting clinical confidence in recognising joint swelling.
Study context
- Population
- Patients with psoriasis (PsO), mainly subclinical psoriatic arthritis (PsA), in two European cohortsmean follow-up 33.0 (±20.9) months
- Participants
- 384 patients
- Exposure
- Subclinical PsA vs PsO
- Subclinical PsAn = 311
- Outcome
- New-onset PsA
Methodological detailslongitudinal, two European cohorts, survival analysis, cumulative incidence functions
- Longitudinal
- Two European cohorts
- Survival analysis
- Cumulative incidence functions
Main finding
As reported in the abstract
Hazard ratio
11.7
95% CI 1.57–86.7
P = 0.016
By group
Subclinical PsA
7.7 per 100 patient-years
incidence rate
Subclinical PsAvs PsO
HR 11.7 (95% CI 1.57–86.7); P = 0.016
Observational data: associations, not effects.
Further findings
Probability of new-onset PsA (CIF) · month 12 and month 36
- Month 12
- 9.4% (95% CI 4.7% to 10.6%)
- Month 36
- 22.7% (95% CI 17.2% to 28.6%)
Symptoms before PsA diagnosis
- Inflammatory symptoms in months immediately prior
- 58.9%
- Prior non-inflammatory symptoms
- 83.9%
PsA presentation pattern
- Peripheral joint swelling (predominant)
- 82.1%
Original publication
Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage. RMD Open. Published 10 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →